Mazanti-Andersen has a strong track record in cross-border equity capital markets transactions. Recent work includes advising on direct issuances of shares, warrants, dual listings and fundraisings. The team is headed up by Lars Lüthjohan Jensen, who has 20 years of experience advising on rights issuances, convertible notes transactions and delistings, with a particular focus on the IT and life sciences sectors.
Legal 500 Editorial commentary
- Profile
- Social
Testimonials
Collated independently by Legal 500 research team.
- 'Great team. In particular, (1) an excellent balance between strictness and pragmatism that comes out of experience, (2) ample cross-border experience, and (3) expertise and advice going beyond legal advice. Lars Lüthjohan Jensen is the key person in the team.'
- 'They are experienced, responsive and practical and a pleasure to work with.'
- 'I have really valued their practical guidance and quick responses.'
Key clients
- 7N A/S
- Allarity Therapeutics A/S and Inc.
- Ascendis Pharma A/S
- Evaxion Biotech A/S
- FluoGuide A/S
- Forward Pharma A/S
- Freetrailer A/S
- Mitsui & Co. Ltd.
- Strategic Investments A/S
- Vald. Birn Holding A/S
Work highlights
Assisted Ascendis Pharma A/S with a $150mn Royalty Funding Agreement.
Assisted Evaxion Biotech A/S with a public offering, including filing of registration statement.
Advised Evaxion with respect to a directed offering towards existing shareholders for subscription of shares and conversion into ADSs listed on Nasdaq New York.
Lawyers
Practice head
Lars Lüthjohan Jensen